LIMR Development, Inc. (LDI) is the business development subsidiary of Lankenau Institute for Medical Research (LIMR). LDI promotes the research conducted by LIMR scientists through technology development and commercialization, including licensing opportunities.

Our researchers are actively working to take their discoveries from bench to bedside by way of an exceptional environment where translational research has a profound impact in both commercial and clinical settings. LDI works closely with LIMR scientists to move their ideas through the patent process, help them explore all of their potential commercial avenues, and ensure they become successful.

Business Development

Product Pipeline

• Coming Soon - Keralogix™ - LDI's proprietary technology for producing normal human keratinocytes that grow far beyond their usual short lifespan
• Cell toxicity, proliferation, and survival
  (TPS) assay CellCountEZ^® - A more accurate, simple, and quicker alternative to existing cell quantitation assays
• OxPhos™, an assay to measure the antioxidant capacity of cells
• Outlicensing and Joint Ventures

Management

• The LIMR Biotech Incubator, whose business model supports early-stage companies
• For more information about LDI and our services, please contact us.

Research at LIMR

LIMR scientists are focusing their research on cancer, cardiovascular disease and diabetes, using basic and preclinical findings to create new diagnostic, prognostic and therapeutic tools for clinical use.

• Cancer Research
• Cardiovascular Research
• Diabetes Research
• Other Research Programs